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Introduction 
Methods 
Conclusions 
We hypothesize that reducing ROS formation through inhibition of NADPH oxidase will 
attenuate myocardial I/R injury by limiting cardiac contractile and diastolic dysfunction 
associated with reduced infarct size and attenuated SO production in myocytes. 
This study showed that both NADPH oxidase inhibitors, gp91 ds-tat and apocynin significantly 
improved post-reperfused cardiac function associated with reduction of infarct size. When 
given at reperfusion, apocynin exerted the cardioprotective effects dose-dependently associated 
with decreased myocyte SO release. The lag time during reperfusion may be due to apocynin 
conversion to diapocynin by tissue peroxidase in order to inhibit NADPH oxidase assembly.  
By contrast, all three gp91 ds-tat concentrations significantly restored post-reperfused cardiac 
function and reduced infarct size, suggesting that these effects are not dose-dependent in this 
concentration range (i.e. 10-80 µM). This study indicates that NADPH oxidase, especially in 
vascular endothelium and myocytes, is a significant source of ROS in myocardial I/R injury.  
Therefore, both NADPH oxidase inhibitors may be potential agents to reduce SO production 
and mitigate reperfusion induced heart damage.   
Results 
minutes of reperfusion by a side arm line proximal to the heart inflow at a rate of 1 ml/min. 
Coronary flow and left ventricular developed pressure (LVDP), which is the left ventricular end-
systolic pressure (LVESP) minus left ventricular end-diastolic  pressure (LVEDP), the maximal 
and minimal rate of LVDP (+dP/dtmax and –dP/dtmin ), and heart rate were taken every 5 minutes 
during baseline and reperfusion using a flow meter (T106, Transonic Systems, Inc., Ithaca, NY) 
and pressure transducer (SPR-524, Millar Instruments, Inc., Houston, TX) respectively. Data was 
recording using a Powerlab Station acquisition system (ADInstruments, Grand Junction, CO). 
Sham hearts received no drug and experienced no ischemia. After 45 minutes of reperfusion, the 
left ventricle was isolated and cross sectioned into three pieces from apex to base.  Two pieces 
were subjected to 1% triphenyltetrazolium chloride (TTC) staining for 15 min at 37oC to detect 
infarct size (viable stained red, infarct left unstained (white)). The third piece was frozen sectioned 
(8 m) and subjected to dihydroethidium (DHE) staining for 2.5 min at room temp to 
fluoroscopically detect SO release for control and apocynin treated groups. Fluorescence intensity 
is expressed in arbitrary units and was quantitated by Image J. 
Statistical Analysis 
All data in the text and figures are presented as means ± S.E.M, and analyzed by analysis of 
variance using post hoc analysis with the Student-Newman-Keuls test for the heart function, 
infarct size and SO data. Probability values of  <0.05 are statistically significant. 
Hypothesis 
Figure 3. Time course of LVDP (top), LVEDP (second to top), +dP/dtmax (second to bottom) and -dP/dtmin (bottom) 
for gp91 ds-tat (left side) and apocynin (right side) treated I/R hearts. I/R hearts exhibited very compromised 
cardiac function during reperfusion. By contrast, I/R hearts treated with 10 M gp91 ds-tat had significant 
restoration for all cardiac function indices. I/R hearts treated with 40 and 80 M gp91 ds-tat had significant 
restoration for LVDP and +dP/dtmax towards the end of reperfusion.  Apocynin (40 M to 1 mM) significantly 
restored all cardiac function variables dose-dependently compared to I/R control. *p<0.05,**p<0.01 vs. I/R control.  
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Figure 4. The graph shows the ratio of infarcted tissue weight to the total tissue weight. Apocynin treatment 
significantly decreased infarct size dose-dependently compared to  untreated control myocardial I/R. Similarly, 
gp91 ds-tat significantly reduced infarct size without a dose-dependent manner compared to  untreated control 
myocardial I/R. (*p<0.05, ** p<0.01). 
Figure 1. Apocynin and gp91 ds-tat inhibit NADPH oxidase subunit assembly and attenuate SO release under I/R 
conditions (upper panel). Structures of apocynin6 and gp91 ds-tat4 are shown in the bottom. Apocynin inhibits 
NADPH oxidase by inhibiting p47phox and p22phox assembly after forming diapocynin by peroxidase5. By 
contrast, gp91 ds-tat contains a docking sequence (ds) which prevents NADPH oxidase p47phox and gp91 
assembly. The tat portion facilitates the peptide diffusion into the cell4. 
   
Figure 5. The representative DHE staining images (40X) among sham (A), control I/R (B), I/R+apocynin 40 µM 
(C), and I/R+apocynin 400 µM (D) (left panel). I/R control and low-dose apocynin (40 µM), exhibited a 
significant increase in SO release compared to sham hearts (##p<0.01).  The graph also shows that apocynin  (400 
µM) significantly reduced SO release dose-dependently compared to control I/R hearts (*p<0.05 ).  
Isolated Rat Heart Preparation 
Male Sprague Dawley (SD) rats (275-325g) were anesthetized intraperitoneally 
(i.p.) (pentobarbital sodium 60 mg/kg and 1,000U of sodium heparin). Hearts were 
rapidly excised and perfused with modified Krebs’ buffer (in mmol/l: 17.0 dextrose, 
120.0 NaCl, 25.0 NaHCO3, 2.5 CaCl2, 0.5 EDTA, 5.9 KCl, and 1.2 MgCl2; 
maintained at 37oC, 80 mm Hg constant pressure, aerated with 95% O2-5% CO2, pH 
keep at 7.3-7.4) by langendorff preparation. Hearts were subjected  to 15 minutes of 
baseline perfusion, 30 minutes of ischemia, and a 45 minute reperfusion period. 5ml 
of plasma (control), or plasma containing apocynin (166 g/mol, Sigma Chemicals; 
40, 400 and 1000 M) or gp91 ds-tat (MW=2452 g/mol, Genemed Synthesis Inc. 
San Antonio TX; 10, 40 and 80 μM) were injected during the first five  
Figure 3.  The representative TTC stained heart cross sections from I/R control, gp91 ds-tat or apocycnin treated 
I/R hearts. Infarct tissue is  unstained (white). Viable is stained red. 
Figure 3. 
Langerdorff preparation 
In myocardial infarction, heart tissue becomes ischemic and completely deprived of oxygenated 
blood and its essential nutrients. Blood must quickly be restored to ischemic heart tissue to avoid 
irreversible cell death. The reperfusion of blood to previously ischemic areas can cause additional 
heart damage, which is referred to myocardial I/R injury. Reperfusion injury is closely related to 
an overproduction of  reactive oxygen species (ROS) once oxygen is available during reperfusion.  
ROS can reduce vascular endothelial-derived nitric oxide (NO) bioavailability resulting in 
reduced flow to ischemic area because NO is a potent vasodilator1.  ROS can also damage the 
mitochondria by opening mitochondrial permeability transition pore, leading to a reduction in 
ATP production and myocyte necrosis/apoptosis2.  ROS can also damage proteins, lipids, and 
DNA and disrupt cell integrity. Furthermore, clinical trials suggest that nonselective antioxidants 
are not effective at attenuating reperfusion injury possibly because they do not specifically target 
the source of ROS.  It has been proposed  that NADPH oxidase, xanthine oxidase, uncoupled 
endothelial NO synthase (eNOS), and mitochondrial dysfunction can serve as ROS sources under 
I/R conditions. Moreover, it has been shown that an overproduction of superoxide (SO) by 
NADPH oxidase can cause dysfunctional modifications that can induce all other ROS sources, 
such as mitochondrial dysfunction and eNOS uncoupling3. So far, there are limited effective 
treatment strategies targeted at limiting reperfusion injury through inhibition of NADPH oxidase. 
In this study, selective peptide NADPH oxidase inhibitor, gp91 ds-tat4, and a well-known 
NADPH oxidase inhibitor, apocynin5, will be used to determine how such inhibition will effect 
myocardial I/R injury (see figure 1).  
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